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Abstract
Background: The Affordable Medicines Facility-malaria (AMFm) is a pilot program that uses price subsidies to increase
access to Artemisinin Combination Therapies (ACTs), currently the most effective malaria treatment. Recent evidence
suggests that availability and affordability of ACTs in retail sector drug shops (where many people treat malaria) has
increased under the AMFm, but it is unclear whether household level ACT use has increased.
Methods and Findings: Household surveys were conducted in two remote regions of Tanzania (Mtwara and Rukwa) in
three waves: March 2011, December 2011 and March 2012, corresponding to 3, 13 and 16 months into the AMFm
implementation respectively. Information about suspected malaria episodes including treatment location and medications
taken was collected. Respondents were also asked about antimalarial preferences and perceptions about the availability of
these medications. Significant increases in ACT use, preference and perceived availability were found between Rounds 1
and 3 though not for all measures between Rounds 1 and 2. ACT use among suspected malaria episodes was 51.1% in
March 2011 and increased by 10.9 percentage points by Round 3 (p = .017). The greatest increase was among retail sector
patients, where ACT use increased from 31% in Round 1 to 49% in Round 2 (p = .037) and to 61% (p,.0001) by Round 3. The
fraction of suspected malaria episodes treated in the retail sector increased from 30.2% in Round 1 to 46.7% in Round 3
(p = .0009), mostly due to a decrease in patients who sought no treatment at all. No significant changes in public sector
treatment seeking were found.
Conclusions: The AMFm has led to significant increases in ACT use for suspected malaria, especially in the retail sector. No
evidence is found supporting the concerns that the AMFm would crowd out public sector treatment or neglect patients in
remote areas and from low SES groups.
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Introduction
Artemisinin-based combination therapies (ACTs) are currently
the most effective medication for the treatment of Plasmodium
falciparum malaria and are the first-line treatment recommended
by the WHO [1]. National programs scaling up access to ACTs
have been linked to substantial reductions in malaria morbidity
and mortality [2], [3]. Despite the fact that this recommenda-
tion has been adopted in the national malaria treatment
guidelines in most countries with malaria, access to ACTs has
been limited due to a number of factors including, but not
limited to, high prices in the private sector [4-6], frequent stock
outs in the public sector [7-10], and challenges in reaching
remote populations [11], [12].
In 2010, the Global Fund to Fight AIDS, TB and Malaria
launched the Affordable Medicines Facility for malaria (AMFm) as
a pilot program in seven countries. The AMFm offers public and
private sector first-line buyers access to heavily subsidized ACTs,
with a primary objective of making low-priced, quality-assured
[13] ACTs widely available through private sector establishments
[14], [15]. Participating countries were also required to implement
supporting interventions (such as awareness campaigns) to increase
the availability and use of the subsidized ACTs. As the private
sector is a common source of malaria treatment [5], [16], by
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encouraging wide-scale availability and awareness of low-priced,
over-the-counter ACTs in private outlets, the AMFm aims to
increase the use of ACTs at the expense of older, less-effective
treatments and artemisinin monotherapies [14], [15], [17]. The
AMFm is innovative in its leveraging of the private sector, but is an
unproven approach to scaling up effective malaria treatment.
Encouraging evidence is emerging that price subsidies do lead to
increased availability and lower prices of private sector ACTs [18],
[19], but it is unclear to what extent this translates into increases in
household level use of ACTs. ACT use could remain unchanged if
malaria patients are unaware that ACTs are the most effective
antimalarials, simply prefer the older antimalarials or if, even in
the presence of subsidies, ACTs remain financially out-of-reach
[20], [21]. These barriers to ACT use could be particularly
important in rural, remote regions [11], [12]. Finally, if malaria
patients seeking ACTs simply switch from public sector to private
sector treatment in the presence of ACT subsidies, the AMFm
could have a negligible impact on overall ACT use.
This study used repeated cross-sectional data collected during
the first 1.5 years of the AMFm in Tanzania to assess trends in
ACT use. Data from periodic household surveys conducted in two
remote regions of Tanzania are used to assess the impact of the
AMFm on malaria treatment seeking, antimalarial purchases and
awareness of and preferences for ACTs. This study is one of the
first to explore whether a private sector subsidy for ACTs, which
has led to a demonstrated increase in availability of low-priced
ACTs, also results in increased use of ACTs for malaria treatment
in remote regions of Africa.
Methods
Study Setting and Overview
The study took place in two regions of Tanzania - Mtwara and
Rukwa (Figure 1) - chosen based on their remoteness, the absence
of non-AMFm malaria interventions, and the presence of
Accredited Drug Dispensing Outlets (ADDOs). ADDOs are
licensed, accredited retail drug outlets approved by the Tanzania
Food and Drug Authority and now present in most regions of
Tanzania. Malaria prevalence estimates in Rukwa and Mtwara
are roughly 7% and 18%, respectively [22]. Both regions are
predominantly rural with the majority of the population engaged
in agriculture. Rukwa is one of the largest and lowest population
density regions in Tanzania and is more remote than Mtwara,
with a distance between Sumbawanga (Rukwa’s regional head-
quarters and main urban center) and Dar es Salaam (1150 km)
more than twice the distance between Mtwara’s main urban
center and Dar es Salaam (556 km) [23].
This research was part of a larger study with a longitudinal
component consisting of ADDO surveys (‘‘retail audits’’) and
customer exit interviews at ADDOs in the two regions, and with a
repeated cross-sectional component consisting of household
surveys in the catchment area of these ADDOs. The data
collection period extended from February 2011 (three months
after ACTs arrived in Tanzania) through May 2012 and included
three rounds of household surveys, occurring in February/March
2011, November/December 2011 and March 2012 (Figure 2).
Methods for the retail audits and exit interviews are described
elsewhere [24]. Survey rounds were originally planned at equally-
spaced intervals but Round 3 was accelerated in order to deliver
results in time for the independent evaluation of the AMFm.
The first AMFm shipment arrived in Tanzania in November
2010 (Figure 2) and ACT orders grew rapidly between 2011 and
the first half of 2012, from roughly 300,000 subsidized ACT
treatments delivered in January 2011 to 29.1 million subsidized
ACT treatments approved and 21.1 million treatments delivered
by June 2012. On average, over one million treatments were
approved each month over this period; however, no orders in
June, July, or September 2011 were approved. Roughly 34% of
the cumulative orders were for the Tanzanian public sector with
the remaining 66% for the private, for-profit sector. Figure 2 also
reproduces results on ACT stocking in ADDOs as reported in the
companion paper by Yadav et al. (2012) [24]. The fraction of
ADDOs stocking ACTs increased from 25% to 90% in Mtwara
and 5% to 70% in Rukwa between January 2011 and May 2012.
Supporting interventions in the form of television and radio
advertisements and print media were scaled-up in early September
2011. By December 2011, 12,700 radio and television spots had
been aired, 48 advertisements placed in newspapers, and several
billboards created. Community outreach initiatives in 12 regions
including the study regions of Mtwara and Rukwa also began in
September 2011, emphasizing the availability and affordability of
the subsidized ACTs to decision makers, caregivers of children
under five, as well as the general community. In addition to these
efforts, other NGOs and community-based organizations carried
out broader campaigns throughout the country around case
management and malaria treatment which could have increased
the reach of the campaign.
Sample Selection
Sample selection for household surveys was conducted as
follows. First, 64 ADDOs were randomly selected among all
ADDOs categorized as ‘‘remote’’ (based on distance to the nearest
major trading center and major road) in Rukwa and Mtwara.
Methods for categorizing remoteness are described in Yadav et al.
(2012) [24]. Shop owners were asked to identify up to five nearby
‘‘Kitongojis’’ (sub-villages) from which their shop drew customers.
From this list, one Kitongoji was randomly selected to conduct a
complete household listing with village leaders. From these lists, 12
households per Kitongoji were randomly selected to be inter-
viewed in each survey round. Households were sampled without
replacement, so that once a household was selected for surveying
in a given round it could not be surveyed again in future rounds.
Of the 64 Kitongojis from which households were drawn, 42 were
in Rukwa and 22 were in Mtwara. The reason for the imbalance
across regions is that an additional region that borders Mtwara
(Lindi region) was included in Round 1 but was dropped from
Rounds 2 and 3 for budgetary reasons. Additionally, one Kitongoji
in Rukwa was dropped for safety reasons. A total sample of 762
households was included in Round 1 and 756 households in
Rounds 2 and 3, with a total of roughly 3900 individuals in each
round.
Data Collection
Informed consent was requested from, and household surveys
were conducted with, the primary female caregiver in the
household (the female responsible for most household health-
care) whenever possible. If the primary female caregiver was
unavailable, an alternative respondent, over the age of 18 and
knowledgeable about health-related decision making, was
interviewed. The respondent was asked whether any member
of the household had suspected malaria in the past four weeks
and, if ‘‘yes’’, the respondent was asked a series of questions
about the steps taken to resolve each reported episode, including
treatment location and medicines purchased. The survey
recorded episodes of ‘‘suspected malaria’’–that is, illnesses that
the respondent or the patient believed were malaria and treated
as such, regardless of whether the illness was diagnosed with a
blood test or by a trained medical professional. For this reason,
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these episodes are referred to as ‘‘suspected malaria’’ throughout
the text. Information on treatment location was recorded for the
first action taken upon suspicion of malaria. The survey also
included questions on knowledge about and preferences for
antimalarials.
All data collection activities were conducted using electronic
data collection tools and developed using Surveybe software
Release 2.1 (Economic Development Initiatives Limited, High
Wycombe United Kingdom).
Analysis
Data were cleaned and analyzed using Stata Version 11.0 SE
(Stata Corporation, College Station, TX). Variable means are
presented as well as p-values on t-tests for differences in variable
Figure 1. Map of the Two Study Regions Selected and Major Towns in Each Region.
doi:10.1371/journal.pone.0070713.g001
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means across survey rounds. Results are unweighted and p-values
are adjusted for clustering within Kitongojis. Given the number of
reported suspected malaria episodes per round (see Table 1) and a
baseline proportion of suspected malaria episodes treated with
ACTs of roughly 50% (see Table 2), the minimum detectable
effect size between Rounds 1 and 2 and Rounds 1 and 3 is 13 and
10 percentage points respectively, assuming 90% power and a 5%
significance level. The study thus has more power to detect
increases in ACT use between Rounds 1 and 3 than between
Rounds 1 and 2. A socioeconomic status index was constructed
based on available data on material assets. Information was
recorded on possession of household items such as radios,
television, livestock, house construction and types of toilet/water
facilities (means of variables included in the SES index are
presented in Table S1). All of these variables were dichotomized
for presence/absence and used to create a principal components
analysis based measure of socio-economic status [25]. This
measure was then broken into tertiles to represent categories of
economic status including ‘‘ultra poor,’’ ‘‘very poor,’’ and ‘‘poor.’’
SES tertiles were used–rather than the more conventional quintile
categorization–because of limited sample size.
Ethical Approval
Ethical approval for the study was granted from the Harvard
School of Public Health and from the Medical Research
Coordinating Committee of the National Institute for Medical
Research, Tanzania. Written consent to participate in the study
was obtained from the primary female caregiver.
Results
Suspected Malaria Episodes
Suspected malaria episodes experienced in the four weeks prior
to survey administration are presented in Table 1. In Round 1,
roughly 6% of individuals (25% of households) report experiencing
a suspected malaria episode. This percentage increased in each
round and was consistently higher in Mtwara than in Rukwa and
higher for children under five than for other ages. Pooling all
rounds together, the fraction of children under five with a
suspected malaria episode was 20% in Mtwara and 10.47% in
Rukwa, similar to the most recent under five malaria burden
estimates based on the Malaria Indicator Survey data collected
from October 2007 to February 2008 in Mtwara (17.96%) and
Rukwa (6.62%) [22].
Treatment Seeking for Suspected Malaria Episodes
The public sector (public clinics and hospitals) was the most
common place for treatment of suspected malaria (Figure 3), with
41.7% of episodes treated in Round 1. The retail sector (ADDOs
and pharmacies) was the second most common treatment location
(30.2% of episodes treated), followed by the episodes where no
treatment was sought (18.7%) and, finally, treatment in the non-
retail private sector (8.9%). Treatment seeking in the public sector
and the non-retail private sector was basically unchanged, with no
significant changes across survey rounds. Retail sector treatment
seeking increased across each round, with most of the increase due
to a decrease in individuals seeking no treatment at all. These
changes were not significant between Rounds 1 and 2, but
between Rounds 1 and 3 retail sector treatment seeking increased
by 16.5 percentage points (p = .0009) and ‘‘no treatment’’
decreased by 15.6 percentage points (p = .0001).
Trends in ACT Usage
ACT use for suspected malaria episodes is presented in Table 2.
In March 2011, 54.6% of households experiencing a suspected
malaria episode treated with ACT. Among those households with
at least one suspected malaria episode, the proportion treating at
least one of those episodes with ACT increased by 13.2 percentage
points (roughly 24%) between Rounds 1 and 3 (p= .004). Increases
in ACT taking of similar magnitudes are seen between Rounds 1
and 3 among all individual episodes (p = .017), among all episodes
in which treatment was sought (p = .01) and in which any
Figure 2. ACT Deliveries, Retail Outlet ACT Stocking and Survey Timing.
doi:10.1371/journal.pone.0070713.g002
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antimalarial was taken (p= .026). Point estimates for changes in
ACT use between Rounds 1 and 2 were positive for these
measures but none of these estimates were significant. ACT usage
was consistently lower in Rukwa than Mtwara. Changes in ACT
use in Rukwa were modest and insignificant, while the change in
Mtwara between Rounds 1 and 3 was substantial at 10.55
percentage points among individuals and 13.08 among house-
holds, though not quite significant at conventional levels (p = .111
for individuals, p = .083 for households).
By far the greatest increases in ACT use were found among
those individuals who sought treatment in the retail sector, where
ACT usage increased from 30.9% in Round 1 to 48.6% in Round
2 (p= .037) and to 61.3% in Round 3 (p,.0001). Nearly 65% of
suspected malaria episodes treated in the public sector in Round 1
were given ACTs, a rate that did not change significantly across
any round. ACT taking for suspected malaria episodes increased
by 11 percentage points between Rounds 1 and 3 for patients five
and older (p = .023), though the change between Rounds 1 and 2
was not significant. In Round 1, rates of ACT taking–although
lowest for the bottom tertile at 48%–did not differ greatly across
SES tertiles. The biggest changes in ACT use were for the bottom
and middle tertiles, at roughly 13 percentage points between
Round 1 and Round 3, but this increase was not quite significant
at conventional significance levels (p = .098 for bottom tertile,
p = .122 for middle tertile).
Preference for and Perceived Availability of ACTs
Respondents were asked several questions about antimalarial
preference for themselves and for a child under five. They were
first asked simply about their preferred antimalarial. They were
then asked how often their preferred antimalarial was available if
needed. Finally they were asked which antimalarial they preferred
if money were no concern. In Round 1, just over half responded
that ACT was preferred for themselves and a similar fraction
preferred ACT if money were no concern (Table 3). Between
Round 1 and Round 2, while the fraction of respondents who
stated that they preferred ACT for themselves did not change
significantly, the fraction who stated a preference for ACT if
money were no concern increased by over 8 percentage points
(p = .009). Between Round 1 and Round 3, both measures of
preference for ACT increased significantly, with the simple
preference increasing by 7.5 percentage points (p = .003) and the
‘‘if money were no concern’’ preference increasing by over 14
percentage points (p,.0001). When asked how often ACTs were
available if needed, the fraction of people who replied ‘‘rarely/
never’’ decreased by roughly 8 percentage points (p = .004) and 13
percentage points (p,.0001) between Rounds 1 and 2 and Round
1 and 3, respectively, with an associated increase in the fraction of
respondents saying ‘‘always/most often’’ and ‘‘sometimes’’. This
pattern of results suggests that knowledge about the superior
effectiveness and the increased availability of ACTs increased
faster than knowledge about the reduction in price due to the
subsidy. While increases in perceived availability of ACTs for a
child were very similar (in magnitude and statistical significance) to
those for the respondent, the significant increases in preference for
ACT for a child were all found between Rounds 1 and 3 and none
between Rounds 1 and 2.
Discussion
This paper provides evidence on trends in ACT usage,
treatment seeking for suspected malaria and patient preferences
for ACTs over the first 15 months of the AMFm. These results
offer critical, complementary evidence to the independent
evaluation of the AMFm, which has been unable to examine
ACT usage by individuals [18], [19]. In addition to capturing
trends in ACT use during rapid increases in retail sector ACT
availability, the data in this paper speak to the AMFm’s impact in
remote areas. This is of particular interest because of the concern
that a private sector approach to scaling up ACT coverage could
have limited impact in communities with the lowest ability to pay
and the least profit potential. Results presented here suggest that
ACT use for suspected malaria increased significantly during the
AMFm scale up in Tanzania. While the overall increase in ACT
use over this 15 month period was moderate at roughly 13
percentage points (24 percent), this increase should be viewed in
Table 1. Suspected Malaria Episodes (Experienced in the Past 4 Weeks) by Age, Region and SES.
March 2011 (Round 1)
December 2011
(Round 2) March 2012 (Round 3)
Change Round 1 to
Round 2
Change Round 1 to
Round 3
Total n
% Reporting
Malaria Total n
% Reporting
Malaria Total n
% Reporting
Malaria % (p-value) % (p-value)
All Households 762 25.07 756 29.63 756 41.93 4.56 (0.0499) 16.87 (0.0000)
All Individuals 3,950 5.97 3,845 8.32 3,935 12.30 2.35 (0.0019) 6.33 (0.0000)
Among Individuals
By Region
Rukwa 2,829 5.55 2,768 7.37 2,736 8.44 1.82 (0.0130) 2.89 (0.0006)
Mtwara 1,121 7.05 1,077 10.77 1,199 21.10 3.72 (0.0527) 14.05 (0.0000)
By Age
Under 5 years 613 10.44 591 11.51 599 15.36 1.07 (0.5344) 4.92 (0.0343)
5 years and over 3,335 5.16 3,254 7.74 3,336 11.75 2.59 (0.0015) 6.59 (0.0000)
By SES
Bottom Tertile 1,318 5.61 1,284 6.23 1,316 12.39 0.62 (0.5179) 6.77 (0.0000)
Middle Tertile 1,314 5.94 1,278 9.23 1,310 12.90 3.30 (0.0084) 6.96 (0.0000)
Upper tertile 1,318 6.37 1,283 9.51 1,309 11.61 3.14 (0.0305) 5.24 (0.0020)
doi:10.1371/journal.pone.0070713.t001
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light of standard take-up rates of new products in private markets.
In a review of both public health programs’ and private
manufacturers’ experience with introduction of new products into
developing country markets, Yamey et al. (2012) concluded that a
5–10 percentage point increase in usage after one year is
considered a success [26]. The shifting to ACT purchases in the
retail sector reported here was particularly substantial, nearly
doubling from 31% to 61%. As retail sector patients were much
less likely to take ACTs than public sector patients initially (31%
vs. 65% at baseline), the AMFm appears to have substantially
narrowed the gap in the likelihood of taking ACTs between
treatment seekers in these sectors. These results also demonstrate
an increase in the perception that ACTs are widely available and
an increasing trend in preference for ACTs to treat both adults
and children, though it is hard to say whether the latter is the cause
or result of the increasing availability of low-priced ACTs.
A central concern about the AMFm is that it could divert
patients from public sector care, where they would have been
more likely to receive proper diagnosis and treatment. These
results do not show evidence of public sector crowd out, but rather
suggest a shift from ‘‘doing nothing’’ to retail sector antimalarial
purchases. Another concern was that the AMFm might only
benefit higher SES households. These results suggest on the
contrary that the biggest increases in ACT use were for the bottom
and middle SES tertiles though these changes were just below
conventional significance levels. These results largely agree with
those from several ACT subsidy pilots and from the paper by Fink
et al. (2013) on the AMFm in Uganda. Fink et al (2013) find a 14
percentage point increase in ACT use among all patients taking
antimalarials during the first year of the AMFm pilot in Uganda
[27]. They also find that the largest increases in ACT use were
among the poorest households and find a significant increase in
ACT use among children under five with fever. Cohen et al.
(2012) piloted an ACT subsidy in Western Kenya and found the
biggest increases in ACT use among low SES households and
found a shift from ‘‘doing nothing’’ to retail sector treatment for
malaria [28]. Cohen et al. (2012) did find, however, some crowd
out of public sector treatment among higher SES households.
Kangwana et al. (2011) pilot an ACT subsidy for children in
Kenya and also found no evidence of public sector crowd out or
significant differences in ACT uptake across SES quintiles [29].
Sabot et al. (2009) pilot the ACT subsidy in Tanzania and also
found that the increase in ACT use was not significantly different
across low and high SES households [30].
A primary objective of the AMFm was to increase ACT use
among children under five with fever. No significant increase in
ACT use for suspected malaria among children was found here,
although the sample size among this subgroup was too small to
detect moderate increases in ACT use. A significant increase in
ACT use for suspected malaria among people over age five was
found. While less of a mortality concern, an increase in
appropriate treatment among this age group is also important
from an economic and public health perspective. For example,
Plasmodium infection among school age children can affect
performance and cognition [31], [32], malaria directly affects
economic and labor productivity [33-36] and there is some recent,
controversial evidence suggestive of higher malaria mortality
among this age group than previously believed [37]. As younger
children become increasingly protected by interventions such as
insecticide-treated bed net distributions, older children are
becoming more important disease reservoirs in some contexts
[38], [39].
ACT use increased more in Mtwara than in Rukwa, possibly
due to somewhat lower availability of ACTs in Rukwa (see Figure 2
and Yadav et al. 2012). Or another factor–such as Rukwa’s
comparative remoteness and/or apparently lower prevalence–
could drive both lower levels of ACT availability and use.
It is important to note that, while the changes in ACT use
between Rounds 1 and 2 were almost consistently positive, they
were often insignificant, whereas increases in ACT use by Round 3
were larger and more significant, despite the fact that ACT
stocking was quite high by Round 2 (Figure 2). This is likely due in
part to the more limited power to detect moderate changes
between Rounds 1 and 2 (discussed in the methods section above)
and also in part to a lag in the translation of increases in subsidized
ACT stocking into increases in ACT use. This lag could be caused
by the time it takes for patients or caregivers to become aware of
the increased availability of ACTs at affordable prices (e.g.
through word-of-mouth) and the dynamics of product adoption
and diffusion, where an initial number of patients/caregivers who
use subsidized ACTs slowly pass on knowledge about their
efficacy, availability and price to the remaining population [40],
[41].
These results should be interpreted with a number of caveats.
First, the data are drawn from only two regions in Tanzania,
purposefully selected for their remoteness, and will have to be
viewed in light of other research on the AMFm to gauge their
generalizability. Second, the presence of ADDOs could have made
Figure 3. Percentage of Suspected Malaria Episodes Treated by Sector, March 2011–March 2012.
doi:10.1371/journal.pone.0070713.g003
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these regions of Tanzania particularly favorable for ACT
distribution in the retail sector. Third, the power to detect
significant changes in ACT use among subgroups and the more
modest changes estimated between Rounds 1 and 2 was limited by
sample size, as the reported rates of suspected malaria were
somewhat lower than expected based on the 2007–2008 MIS. An
analysis that purposively sampled higher malaria risk households
could have explored trends in ACT use among sub-groups with
more accuracy.
A number of considerations arise from the measurement of
suspected, but in many cases unconfirmed, malaria in the survey
tool. Without local parasite prevalence data spanning the period of
study, it is difficult to gauge the extent to which the increase in
suspected malaria episodes reported across rounds reflects a true
increase in malarial infections or rather an increase in the belief
that malaria-like illnesses are actually malaria. It is possible that
perceptions about the likelihood that an illness was malaria
increased as a result of the AMFm. If many of these cases are not
truly malaria, increases in ACT use are not necessarily desirable.
On the other hand, if many true malaria cases are ‘‘missed’’
because, for example, caregivers do not recognize symptoms, than
an increase in the recognition of malarial illness should have a
positive effect on morbidity. Since suspected malaria (regardless of
symptoms) is what triggers treatment seeking, it was important for
this study to utilize a broad, self-reported malaria measure, but this
may limit the extent to which these results can be compared to
estimates from MIS surveys, as the latter ask about treatment
seeking for fever episodes among children under five. Finally, it is
possible that caregivers may misremember episodes or how they
were treated, but this measurement error should not have changed
systematically across survey rounds, so an analysis of trends in
ACT usage should not be compromised.
An important concern in interpreting these results stems from
the absence of a control group or counterfactual policy environ-
ment. Even in the absence of the AMFm, ACT use could have
been increasing over time in Tanzania, for example if awareness of
ACT effectiveness or private sector competition increased. This
would lead to an overstatement of the role of the AMFm. It is
questionable how much the increase in ACT use found here was
driven by non-AMFm factors, however, as those factors would not
have removed a major barrier to ACT adoption–namely, the high
price of unsubsidized ACTs. While it is possible that the
opportunity to receive a blood-based diagnosis was increasing
for public sector patients during this period, this is unlikely to have
driven the results we find here since no significant increase in
public sector treatment seeking or ACT taking among public
sector patients was found.
These results could also be understating the impact of the
AMFm, as data collection began several months after the first–
albeit small (.25 million doses)–batch of subsidized ACTs arrived
in Tanzania and ended before the conclusion of the AMFm.
Finally, these results cannot be seen as the result of a completely
unrestricted market for subsidized ACTs as, starting September
2011, the AMFm Secretariat began using a ‘‘rationing mecha-
nism’’, approving only a fraction of private sector orders for co-
payments on subsidized ACTs [18].
A factory-gate subsidy for ACTs appears to have been effective
at increasing usage of recommended malaria treatment, even in
poor, remote communities. Firm conclusions about the impact of
the AMFm in Tanzania or more broadly cannot be drawn from
these findings given their geographic restrictions. However, these
results are cause for optimism that the substantial, national-scale
increases in ACT availability and affordability attributed to the
AMFm that have been reported elsewhere are contributing to
corresponding increases in usage of the drugs and therefore
progress towards the achievement of national and global goals of
widespread, prompt use of ACT treatment.
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